8-K: Brainstorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Brainstorm Cell Therapeutics reported its full year 2024 financial results, highlighting progress with its NurOwn ALS treatment and a warrant inducement agreement to raise $1.64 million.

Summary

• Brainstorm Cell Therapeutics announced its financial results for the year ended December 31, 2024.
• The company is focused on developing and commercializing innovative therapies for neurodegenerative diseases, particularly NurOwn for ALS.
• They are in advanced preparations for a Phase 3b trial of NurOwn, involving approximately 200 ALS participants.
• The FDA has agreed to a Special Protocol Assessment (SPA) for the trial, reducing regulatory risk.
• The company has also aligned with the FDA on Chemistry, Manufacturing, and Controls (CMC) aspects.
• A warrant inducement agreement is expected to raise approximately $1.64 million, closing around April 1, 2025.
• Cash, cash equivalents, and short-term bank deposits were approximately $0.4 million as of December 31, 2024, compared to $1.5 million as of December 31, 2023.
• Research and development expenditures for 2024 were $4.7 million, compared to $10.7 million in 2023.
• General and administrative expenses for 2024 were approximately $7.0 million, down from $10.7 million in 2023.
• The net loss for 2024 was approximately $11.6 million, compared to a net loss of $17.2 million in 2023.
• Net loss per share for 2024 was $2.31, compared to $6.00 in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to progress in clinical trials, FDA agreement on SPA, and reduced net loss. However, low cash reserves and the need for additional funding temper the optimism.

Positives

• The FDA agreement on a Special Protocol Assessment (SPA) for the Phase 3b trial of NurOwn reduces regulatory risk.
• The company is aligned with the FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of the trial.
• The company expects to raise $1.64 million through a warrant inducement agreement.
• The net loss decreased from $17.2 million in 2023 to $11.6 million in 2024.
• The company regained compliance with Nasdaq's minimum bid price requirement.

Negatives

• Cash, cash equivalents, and short-term bank deposits decreased from $1.5 million as of December 31, 2023, to approximately $0.4 million as of December 31, 2024.

Risks

• The company's ability to obtain regulatory approval for NurOwn is subject to inherent uncertainties.
• The company's ability to raise additional capital is a risk factor.
• The company's ability to continue as a going concern is a risk factor.
• The company's future interactions with the FDA may not have productive outcomes.

Future Outlook

The company is focused on advancing the Phase 3b trial of NurOwn for ALS and working towards regulatory approval. They believe NurOwn has the potential to make a meaningful difference in the lives of ALS patients.

Management Comments

• Chaim Lebovits, President and Chief Executive Officer of BrainStorm, stated that 2024 was a year of resilience and progress.
• He emphasized the company's focus on gaining regulatory approval of NurOwn in ALS and their close collaboration with the FDA.
• He believes that if approved, NurOwn has the potential to make a meaningful difference in the lives of ALS patients.

Industry Context

Brainstorm is operating in the competitive field of neurodegenerative disease therapeutics, specifically targeting ALS. The strategic partnership with Pluri to support manufacturing for the Phase 3b NurOwn trial is a move to enhance operational readiness and production capabilities, which is crucial in this industry.

Comparison to Industry Standards

• Comparing Brainstorm to companies like Amylyx Pharmaceuticals, which received FDA approval for Relyvrio for ALS, highlights the regulatory hurdles and the potential market for effective ALS treatments.
• The Phase 3b trial size of approximately 200 participants is a standard approach for late-stage clinical trials in rare diseases like ALS.
• The SPA agreement with the FDA is a positive sign, as it indicates alignment on trial design and endpoints, similar to what other companies seek in their drug development programs.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the warrant inducement agreement.
• ALS patients and their families could benefit from the potential approval of NurOwn.
• Employees are impacted by the company's ability to secure funding and advance its clinical programs.

Next Steps

• Closing the warrant inducement agreement expected on or about April 1, 2025.
• Advancing preparations for the Phase 3b trial of NurOwn in ALS.
• Continuing to work closely with the FDA to achieve regulatory approval of NurOwn.

Key Dates

Keywords

NurOwn, ALS, Brainstorm Cell Therapeutics, Financial Results, Phase 3b Trial, SPA, MSC-NTF, Neurodegenerative Diseases, Warrant Inducement, FDA